AbbVie surprised investors with its hepatitis C success. Will it last?

AbbVie surprised investors with its hepatitis C success. Will it last?

Source: 
Biopharma Dive
snippet: 

By the time AbbVie brought its first drug for hepatitis C to market, in December 2014, it was already too late.

Twelve months earlier, Gilead Sciences had secured U.S. approval for Sovaldi (sofosbuvir), offering hepatitis C patients a once-daily treatment regimen capable of clearing the virus in as little as three months.